Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025)
Historic Total Non-Current Liabilities for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q2 2025 value amounting to -$1.1 million.
- Ascentage Pharma Group International's Total Non-Current Liabilities changed N/A to -$1.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.1 million, marking a year-over-year change of. This contributed to the annual value of $161.3 million for FY2024, which is 2380.4% down from last year.
- According to the latest figures from Q2 2025, Ascentage Pharma Group International's Total Non-Current Liabilities is -$1.1 million.
- Ascentage Pharma Group International's Total Non-Current Liabilities' 5-year high stood at $207.7 million during Q4 2023, with a 5-year trough of -$1.1 million in Q2 2025.
- In the last 3 years, Ascentage Pharma Group International's Total Non-Current Liabilities had a median value of $163.9 million in 2024 and averaged $123.5 million.
- The largest annual percentage gain for Ascentage Pharma Group International's Total Non-Current Liabilities in the last 5 years was 2111.33% (2024), contrasted with its biggest fall of 2111.33% (2024).
- Over the past 3 years, Ascentage Pharma Group International's Total Non-Current Liabilities (Quarter) stood at $207.7 million in 2023, then decreased by 21.11% to $163.9 million in 2024, then plummeted by 100.65% to -$1.1 million in 2025.
- Its Total Non-Current Liabilities was -$1.1 million in Q2 2025, compared to $163.9 million in Q4 2024 and $207.7 million in Q4 2023.